Program
omaveloxolone
Also written as “Omaveloxolone”, “Omaveloxolone Capsules, 2.5 mg” and “Omaveloxolone Capsules, 5 mg”.
Its studies are mostly in Friedreich Ataxia · Inflammation · Mitochondrial Myopathies · Melanoma · Breast Neoplasms, led by Biogen.
Drug pageOmaveloxolone: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 192 open or running | phase 3since Apr 11, 2025 | Dec 30, 2013 | Nov 16, 2027phase 3 · NCT06953583 |
Also a collaborator on its studies: AbbVie, Celerion, Q2 Solutions, Altasciences and Covance.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Dec 30, 2013.
- May 16, 2014Phase 2 study in Breast NeoplasmsNCT02142959 · 187 enrolled · United States
- Sep 30, 20142 phase 2 studiesNCT02255435, NCT02255422
- Oct 3, 2014Phase 2 study in MelanomaNCT02259231 · 41 enrolled · United States
- Jun 9, 2015Named omaveloxoloneINNProposed as its International Nonproprietary Name in WHO's List 113
- Sep 6, 2018Phase 1 study in HealthyNCT03664453 · 32 enrolled · United States
- Mar 26, 2019Phase 1 study in Hepatic ImpairmentNCT03902002 · 48 enrolled · United States
- Apr 25, 2019Phase 1 study in Healthy Male SubjectsNCT03931590 · 8 enrolled · United States
- Jul 2, 2019Phase 1 study in Healthy Adult SubjectsNCT04008186 · 61 enrolled · United States
- Jun 8, 20232 phase 1 studiesNCT05909644, NCT05927649
- Sep 13, 2023Phase 1 study in Friedreich AtaxiaNCT06054893 · 33 enrolled · United States
- Sep 23, 2024Phase 1 study in Healthy VolunteerNCT06612879 · 12 enrolled · United States
- Apr 11, 2025Phase 3 study in Friedreich AtaxiaNCT06953583 · 255 enrolled · United States, Australia, Austria and more
- Jun 5, 2025Phase 1 study in Healthy VolunteerNCT07019064 · 52 enrolled · United States
- Aug 28, 2025Phase 1 study in Healthy VolunteerNCT07149415 · 22 enrolled · United States
- Dec 9, 2025Phase 1 study in Healthy VolunteerNCT07297199 · 70 enrolled · United States
Ahead
- Nov 16, 2027Primary completion: phase 3 study in Friedreich AtaxiaNCT06953583
- Jun 4, 2030Primary completion: phase 1 study in Friedreich AtaxiaNCT06054893
TargetBeta
“Nuclear factor erythroid 2-related factor 2 activator”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07297199Healthy Volunteer · United States | 1 | Completed | May 1, 2026 | 70 |
| NCT07149415Healthy Volunteer · United States | 1 | Completed | Oct 16, 2025 | 22 |
| NCT07019064Healthy Volunteer · United States | 1 | Completed | Aug 19, 2025 | 52 |
| NCT06953583Friedreich Ataxia · United States, Australia, Austria and more | 3 | Active, not recruiting | Nov 16, 2027 | 255 |
| NCT06612879Healthy Volunteer · United States | 1 | Completed | Mar 11, 2025 | 12 |
| NCT06054893Friedreich Ataxia · United States | 1 | Active, not recruiting | Jun 4, 2030 | 33 |
| NCT05927649Health Adult Subjects · United States | 1 | Completed | Sep 1, 2023 | 30 |
| NCT05909644Healthy Adult Subjects · United States | 1 | Completed | Aug 30, 2023 | 20 |
| NCT04008186Healthy Adult Subjects · United States | 1 | Completed | Aug 18, 2019 | 61 |
| NCT03931590Healthy Male Subjects · United States | 1 | Completed | May 31, 2019 | 8 |
| NCT03902002Hepatic Impairment · United States | 1 | Completed | Jan 27, 2020 | 48 |
| NCT03664453Healthy · United States | 1 | Completed | Nov 20, 2018 | 32 |
| NCT02259231Melanoma · United States | 2 | Completed | May 9, 2018 | 41 |
| NCT02255435Friedreich Ataxia · United States, Australia, Austria and more | 2 | Completed | Oct 31, 2019 | 172 |
| NCT02255422Mitochondrial Myopathies · United States, Denmark | 2 | Completed | Nov 2, 2017 | 53 |
| NCT02142959Breast Neoplasms · United States | 2 | Completed | Apr 30, 2015 | 187 |
| NCT02065375Inflammation · United States | 2 | Completed | Sep 30, 2014 | 109 |
| NCT02029729Neoplasm Metastasis · United States | 1 | Completed | Oct 1, 2015 | 11 |
| NCT02029716Inflammation · United States | 1 | Completed | Apr 1, 2014 | 109 |
How it is read
Names in the registry
- “Omaveloxolone”, 9 entries
- “omaveloxolone”, 2 entries
- “Omaveloxolone Capsules, 2.5 mg”, 1 entry
- “Omaveloxolone Capsules, 5 mg”, 1 entry
- “Omaveloxolone Capsules, 10 mg”, 1 entry
Conditions, from the studies’ own filings
- Friedreich Ataxia, 3 studies
- Inflammation, 2 studies
- Mitochondrial Myopathies, 1 study
- Melanoma, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.